These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 10390298

  • 1. Previous exposure to measles, mumps, and rubella--but not vaccination during adolescence--correlates to the prevalence of pancreatic and thyroid autoantibodies.
    Lindberg B, Ahlfors K, Carlsson A, Ericsson UB, Landin-Olsson M, Lernmark A, Ludvigsson J, Sundkvist G, Ivarsson SA.
    Pediatrics; 1999 Jul; 104(1):e12. PubMed ID: 10390298
    [Abstract] [Full Text] [Related]

  • 2. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
    Matter L, Germann D, Bally F, Schopfer K.
    Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
    [Abstract] [Full Text] [Related]

  • 3. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A, Gerike E.
    Vaccine; 2000 Jan 31; 18(14):1382-92. PubMed ID: 10618536
    [Abstract] [Full Text] [Related]

  • 4. Low mumps antibody levels induced by mumps-measles-rubella vaccinations in type 1 diabetic children.
    Hiltunen M, Hyöty H, Leinikki P, Akerblom HK, Tuomilehto J, Vesikari T.
    Diabet Med; 1994 Dec 31; 11(10):942-6. PubMed ID: 7895458
    [Abstract] [Full Text] [Related]

  • 5. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K, Nicoara C, Germann D, Matter L.
    Schweiz Med Wochenschr; 1998 Apr 25; 128(17):649-57. PubMed ID: 9622837
    [Abstract] [Full Text] [Related]

  • 6. Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection.
    Cilla G, Peña B, Marimón JM, Pérez-Trallero E.
    Vaccine; 1996 Apr 25; 14(6):492-4. PubMed ID: 8782345
    [Abstract] [Full Text] [Related]

  • 7. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines.
    Crovari P, Gabutti G, Giammanco G, Dentico P, Moiraghi AR, Ponzio F, Soncini R.
    Vaccine; 2000 Jun 15; 18(25):2796-803. PubMed ID: 10812221
    [Abstract] [Full Text] [Related]

  • 8. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.
    Usonis V, Bakasenas V, Kaufhold A, Chitour K, Clemens R.
    Pediatr Infect Dis J; 1999 Jan 15; 18(1):42-8. PubMed ID: 9951979
    [Abstract] [Full Text] [Related]

  • 9. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis.
    Flynn JT, Frisch K, Kershaw DB, Sedman AB, Bunchman TE.
    Adv Perit Dial; 1999 Jan 15; 15():269-72. PubMed ID: 10682116
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE, Kumar ML, Whitwell JK, Staehle BO, Rome LP, Dinakar C, Hurni W, Nalin DR.
    Pediatr Infect Dis J; 1996 Aug 15; 15(8):687-92. PubMed ID: 8858673
    [Abstract] [Full Text] [Related]

  • 12. Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination.
    Boulianne N, De Serres G, Ratnam S, Ward BJ, Joly JR, Duval B.
    Vaccine; 1995 Nov 15; 13(16):1611-6. PubMed ID: 8578850
    [Abstract] [Full Text] [Related]

  • 13. Serologic responses to measles, mumps, and rubella (MMR) vaccine in healthy infants: failure to respond to measles and mumps components may influence decisions on timing of the second dose of MMR.
    Mitchell LA, Tingle AJ, Décarie D, Lajeunesse C.
    Can J Public Health; 1998 Nov 15; 89(5):325-8. PubMed ID: 9813922
    [Abstract] [Full Text] [Related]

  • 14. Response to measles-mumps-rubella vaccine in children on dialysis.
    Schulman SL, Deforest A, Kaiser BA, Polinsky MS, Baluarte HJ.
    Pediatr Nephrol; 1992 Mar 15; 6(2):187-9. PubMed ID: 1571219
    [Abstract] [Full Text] [Related]

  • 15. Decline in rates of seropositivity for measles, mumps, and rubella antibodies among previously immunized children treated for acute leukemia.
    Feldman S, Andrew M, Norris M, McIntyre B, Iyer R.
    Clin Infect Dis; 1998 Aug 15; 27(2):388-90. PubMed ID: 9709893
    [Abstract] [Full Text] [Related]

  • 16. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients.
    King SM, Saunders EF, Petric M, Gold R.
    Bone Marrow Transplant; 1996 Apr 15; 17(4):633-6. PubMed ID: 8722367
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines.
    Miller E, Hill A, Morgan-Capner P, Forsey T, Rush M.
    Vaccine; 1995 Jun 15; 13(9):799-802. PubMed ID: 7483800
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.